Department of Oncology, The First Affiliated Hospital of Anhui Medical Universtiy, Hefei, China.
Burning Rock Biotech, Guangzhou, China.
Thorac Cancer. 2020 Sep;11(9):2717-2722. doi: 10.1111/1759-7714.13569. Epub 2020 Jul 13.
A 53-year-old man diagnosed with disease stage IIIB pulmonary adenocarcinoma underwent chemotherapy and radiotherapy in the first-line setting. After disease progression, he received targeted therapy because of subsequent detection of EGFR exon 19 del mutation. Following an increase in his adrenal metastases, a combination of immunotherapy and antiangiogenic therapy (sintilimab plus bevacizumab) was commenced. After one month, imaging showed that the adrenal metastases had shrunk and a progression-free survival (PFS) of 6.0 months was achieved. In this case, we showed that the PD1 inhibitor sintilimab plus bevacizumab was effective in a refactory advanced EGFR-mutant NSCLC with positive PD-L1 expression. KEY POINTS: Our case report provides clinical evidence of the durable response of a patient with advanced EGFR-mutant lung adenocarcinoma to a combination of immunotherapy and anti-angiogenic agent, sintilimab and bevacizumab, as subsequent-line therapy. Sintilimab and bevacizumab combination therapy was well-tolerated and effective, resulting in dramatic tumor reduction and improvement in clinical symptoms.
一位 53 岁男性被诊断为 IIIB 期肺腺癌，在一线治疗中接受了化疗和放疗。疾病进展后，由于随后检测到 EGFR 外显子 19 缺失突变，他接受了靶向治疗。在肾上腺转移增加后，开始联合免疫治疗和抗血管生成治疗（信迪利单抗联合贝伐珠单抗）。一个月后，影像学显示肾上腺转移缩小，无进展生存期（PFS）达到 6.0 个月。在这种情况下，我们表明 PD1 抑制剂信迪利单抗联合贝伐珠单抗对具有阳性 PD-L1 表达的难治性晚期 EGFR 突变型 NSCLC 有效。关键点：我们的病例报告为晚期 EGFR 突变型肺腺癌患者随后接受免疫治疗和抗血管生成药物信迪利单抗联合贝伐珠单抗联合治疗的持久反应提供了临床证据。信迪利单抗联合贝伐珠单抗治疗耐受性良好，疗效显著，肿瘤明显缩小，临床症状改善。
